Andelyn Biosciences, which is a US-based cell and gene therapy Contract Development and Manufacturing Organization – CDMO and ENCell Co., a Korea-based advanced biopharmaceutical CDMO, on April 22, 2026, announced the signing of a collaboration agreement in order to establish a strategic manufacturing bridge between the United States and Asia-Pacific – APAC regions which will help accelerate life-changing gene therapy manufacturing.
It is well to be noted that the collaboration draws on the world-class GMP manufacturing capabilities, technical expertise and extensive regional networks of both the companies to accelerate the development and manufacturing along with global delivery of client programmes that bring next-generation gene therapies for patients all over the world.
This collaboration of global delivery of life-changing gene therapy manufacturing allows a seamless dual-hemisphere workflow. The partnership is a simple, low-cost platform that eliminates the regulatory and logistical hurdles to international growth, offering a direct route between US and APAC manufacturing hubs.
Additionally, permitting in-country manufacturing for in-country clinical trials allows regional supply chains to address the specific needs of local patient populations, effectively cutting the lead times and also fast-tracking the path when it comes to commercialisation.